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Abstract
Background: Chronic edema is a condition posing a high burden on patients. The primary aim of the study was
to assess the health-related quality of life (QoL) of adult patients living with chronic edema.
Methods and Results: As part of an international, multicenter, prospective study, we prospectively assessed the
health-related QoL of adult patients living with a chronic edema using a disease-specific tool and a generic one.
In total, 1094 patients were included, aged 57 years on average. The average EQ-5D and LYMQOL visual
analogue scale (VAS) scores were equal to 63.6 (SD= 20.2) and 6.3 (SD= 2.0), respectively. After adjustment,
the EQ-5D VAS was explained by LYMQOL VAS (b = 7.85; p< 0.001), age (b= -0.08; p= 0.02), obesity
(b = -1.89; p = 0.001), and male gender (b = 3.32; p = 0.002). As for the LYMQOL VAS, it was independently
associated with EQ-5D VAS (b= 0.07; p< 0.001), LYMQOL function (b=-0.21; p< 0.001), and LYMQOL
mood (b=-0.49; p< 0.001).
Conclusion: This study confirms that patients living with a chronic edema experience a poor disease-specific
and generic health-related QoL.
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Introduction
Chronic edema is characterized by persistent swellingof a body part that has been present for >3 months.1
Chronic edema types include lymphedema, lymphovenous
edema, lipedema, and gravitational edema. It can affect the
upper or lower limbs, the trunk, genitals, head, face, neck, or
a combination of these.2 Chronic edema is a chronic, incur-
able condition and poses a high burden on patients due to pain
and swelling. Its prevalence has been estimated at 4 per 1000
population3; in spite of this high burden, the implications of
chronic edema are not well understood.4
Published evidence suggests that chronic edema is asso-
ciated with high levels of functional impairment, anxiety,
depression, social impairment, and physical symptoms in-
cluding discomfort and pain.5–7 Poor health-related quality of
life (QoL) is related to pain, skin quality, limb mobility, and
the frequency of cellulitis/erysipelas and acute inflammatory
episodes. Assessing the health-related QoL of patients with
chronic edema is of utmost importance to manage patients, to
serve as a baseline in the assessment of novel interventions
and to develop patient-centered treatment guidelines. However,
the vast majority of studies focus on breast cancer–related
chronic edema or lower limb chronic edema, and little is known
about the impact of chronic edema on health-related QoL.
The present study is part of the LIMPRINT project, an
international epidemiological study on chronic edema led by
the International Lymphoedema Framework. We hereafter
analyze the health-related QoL component of the LIMPRINT
project.
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The primary aim of the study was to assess the health-
related QoL of adult patients living with chronic edema.
Methods
Study design and setting
The LIMPRINT study is an international, multicenter,
prospective, observational study aimed to determine the
impact of chronic edema in adults identified in health ser-
vices. Patients have been included between 2014 and 2017 in
18 inpatient and outpatient health care centers in six countries
(i.e., Canada, Denmark, France, Ireland, Japan, and Turkey).
In each center, all consecutive patients aged ‡18 years,
having chronic edema for >3 months, and able to understand
the study and to give informed consent were included. Pa-
tients who were unwilling or unable to participate or were
receiving end-of-life care were not included. Chronic edema
were identified using a case ascertainment method with one
standard questionnaire (CoreTool). The methodology for the
overall study is published separately.
Data collection
Demographic and clinical data collection was conducted
using the CoreTool questionnaire. It was completed by a
health care professional attending the patient and covers the
following 13 domains: type of facility in which data are
collected, demographics, level of obesity, mobility, rele-
vant comorbidities, classification of primary or secondary
lymphedema, edema history, cellulitis history, categories of
treatment, site of swelling, wound area, access to treatment,
and subjective control of swelling.
Two health-related QoL questionnaires were completed
by the patients themselves: LYMQOL and EQ-5D-3L.
LYMQOL is a validated condition-specific QoL assess-
ment instrument.8 Separate tools were developed for upper
and lower limb lymphedema. The tools are patient-
completed questionnaires with 32 items covering four
domains: symptoms, body image/appearance, function,
and mood. Each item is scored between 1 (not at all) and 4
(a lot). A total score is calculated for each domain by
adding the scores together and dividing by the total number
of items answered.
In addition, LYMQOL has an overall QoL visual analogue
scale (LYMQOL VAS) rating scored 0–10. EQ-5D-3L is a
generic QoL instrument applicable to a wide range of health
conditions and provides a simple descriptive profile and
single-index value for health status.9 The EQ-5D-3L com-
prises the following five dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression. Each
dimension has three levels: no problems, some problems, and
extreme problems. For each dimension, the patient’s choice
results into a one-digit number. The digits for the five di-
mensions can be combined into a five-digit number that de-
scribes the patient’s health state.
In addition, EQ-5D VAS records the patient’s self-rated
health on a visual scale between ‘‘100 = best imaginable
health state’’ and ‘‘0=worst imaginable health state.’’ As re-
commended for international multicenter studies, utility values
were derived using a single-value set, that is, the French one.10
All data were entered into a remote data entry application
providing a secure online data management system.
Ethical aspects
The LIMPRINT study was conducted in accordance with
current ethical approval and research governance regulatory
frameworks applicable to the countries concerned. All patients
signed a written informed consent before participation.
Statistical methods
Quantitative variables were described in the study popu-
lation with means and standard deviations (SD) or median
and first and third quartiles (Q25–Q75) depending on the
distribution tested with the Shapiro–Wilk statistic. Qualita-
tive variables were described with frequencies and percent-
ages. Continuous variables were compared with the Student’s
t-test when distribution was normal, or the Mann-Whitney
rank-sum test otherwise. For categorical variables, percent-
ages were compared with chi-square analysis or Fisher’s
exact test. Pearson’s correlation coefficients were used to
summarize the relationships between continuous variables.
Then, two-multiple linear regression models were im-
plemented to identify the variables independently associated
with the EQ-5D and LYMQOL VAS. Only variables sig-
nificantly associated with the cost difference in bivariate
analyses were included in the multivariate models. All sta-
tistical tests were performed using a bilateral 5% type-one
risk. Statistical analyses were performed with the statistical
software SAS version 9.2 (SAS Institute, Cary, NC).
Results
A total of 1094 patients completed the QoL tools and were
included in the analysis. Patients were aged 57 years on av-
erage (SD= 14.5), 85.2% were female, 36.1% were obese or
morbidly obese, and 85.5% had a secondary edema (Table 1).
The average EQ-5D and LYMQOL VAS scores were equal
to 63.6 (SD = 20.2) and 6.3 (SD = 2.0), respectively. Both
were positively and significantly correlated (q= 0.8; p< 0.001).
Regarding patients with an arm edema, the highest impact was
on the symptoms and appearance domains, while it was on
function and appearance for leg edema. Overall, the impact on
all domains was higher in the case of a leg edema compared with
an arm one. LYMQOL domain scores are scaled in a negative
direction: the higher the score, the higher the impact and the
poorer the QoL. The number of patients by country varied be-
tween 24 (Ireland) and 653 (Turkey), and 62.4% of them were
included in a specialist lymphedema service (Table 2).
The majority of patients had one of the following specific
chronic edema treatments: compression garment, skin care
advice, and manual lymphatic drainage (Table 3). More than
one third of patients reported at least one barrier in access to
specific lymphedema treatment. Overall, 41.1% of patients
declared a positive subjective control of swelling.
The EQ-5D-3L VAS was positively and significantly cor-
related with the LYMQOL VAS (q= 0.79; p< 0.001). It was
negatively and significantly correlated with all the LYMQOL
domains with correlation coefficients ranging from -0.46
(function domain) to -0.61 (appearance domain) (Table 4).
In the first multivariate analysis, the EQ-5D VAS was in-
dependently associated with LYMQOL VAS (b= 7.85;
p < 0.001), age (b = -0.08; p= 0.02), obesity (b =-1.89;
p = 0.001), and male gender (b = 3.32; p = 0.002) (Table 5).
Country, infection, and cellulitis status were not significantly
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associated with EQ-5D VAS. Hence EQ-5D VAS was sig-
nificantly higher when LYMQOL VAS was higher, when the
patient was younger, nonobese, and a male. On average, a one-
point increase in LYMQOL VAS was associated with a 7.85
points increase in EQ-5D VAS; a 1-year increase in age was
associated with a 0.08 point decrease in EQ-5D VAS; obese
status was associated with a 1.89 point decrease in EQ-5D VAS;
and male gender was associated with a 3.32 points increase in
EQ-5D VAS. The adjusted model R-square was equal to 0.63.
In the second multivariate analysis, the LYMQOL VAS
was independently associated with EQ-5D VAS (b = 0.07;
p < 0.001), LYMQOL function (b = -0.21; p < 0.001), and
LYMQOL mood (b = -0.49; p< 0.001) (Table 5). None of the
other demographic and clinical variables were significantly
associated with LYMQOL VAS. Hence LYMQOL VAS was
significantly higher when EQ-5D VAS was higher, and when
LYMQOL function and mood were lower. On average, a one-
point increase in EQ-5D VAS was associated with a 0.07
point increase in LYMQOL VAS; a one point increase in
LYMQOL function was associated with a 0.21 point decrease
in LYMQOL VAS; and a one point increase in LYMQOL
mood was associated with a 0.49 point decrease in LYMQOL
VAS. The adjusted model R-square was equal to 0.66.
Discussion
In this international, prospective, multicenter study on
1094 patients with chronic edema, the average health-related
QoL measured with the LYMQOL VAS was equal to 6.3
(SD= 2.0) and the average EQ-5D VAS score was equal to
63.6 (SD = 20.2).
Results from this study suggest that chronic edema has a
considerable impact on a patient’s health-related QoL. This is
in line with several previously published studies in various
countries.1,5,6,11–13 In a sample of patients living with a
lower-limb chronic edema in Ireland, Green and Meskell
reported a higher score for each of the four LYMQOL do-
mains (i.e., a poorer QoL) and a poorer overall QoL measured
Table 1. Patients’ Characteristics
Mean (–SD) or N (%)
Women 932 (85.2)
Age (years) 57 (–14.5)
Obesity
Morbidly obese 67 (6.1)
Obese 328 (30.0)
Normal weight 670 (61.2)
Underweight 27 (2.5)
Classification of lymphedema
Primary 159 (14.5)
Secondary 935 (85.5)
Secondary swelling due to
Cancer 675 (72.2)
No cancer 260 (27.8)
Lymphedema location
Upper limb only 565 (51.8)
Lower limb only 525 (48.2)
Lymphedema duration
<1 year 332 (30.3)
1 year to <5 years 349 (31.9)
5–10 years 170 (15.5)
>10 years 243 (22.2)
Infection last year due to swelling 189 (17.4)
Hospitalization because of infection 119 (10.9)
Swelling and wound 82 (7.5)
LYMQOL
Arm function 1.73 (–0.62)
Leg function 2.21 (–0.85)
Arm appearance 1.96 (–0.77)
Leg appearance 2.27 (–0.93)
Arm symptoms 2.04 (–0.67)
Leg symptoms 2.13 (–0.81)
Arm mood 1.87 (–0.72)
Leg mood 1.89 (–0.79)
LYMQOL VAS 6.3 (–2)
EQ-5D
Mobility 1.53 (–0.55)
Self-care 1.42 (–0.57)
Usual activities 1.71 (–0.59)
Pain/discomfort 1.79 (–0.59)
Anxiety/depression 1.61 (–0.63)
EQ-5D VAS 63.6 (–20.2)
VAS, visual analogue scale.
Table 2. Distribution by Country
and Facility Type
n %
Country
Turkey 653 59.69
France 198 18.10
Denmark 115 10.51
Japan 60 5.48
Canada 44 4.02
Ireland 24 2.19
Facility type
Specialist lymphedema service 683 62.43
Acute hospital outpatient 307 28.06
Other 77 7.04
Acute hospital inpatient 18 1.65
Nursing home 9 0.82
Table 3. Treatment and Disease Control
n %
Positive subjective control of swelling 450 41.13
Access to lymphedema treatment 316 28.88
Treatment not available for free 216 19.74
Treatment not available within
a reasonable traveling distance
Distance prevents access to treatment 356 35.54
Main treatments
Compression garment 631 58.00
Skin care advice 578 53.13
Manual lymphatic drainage 547 50.28
Multilayer bandage 478 43.93
Cellulitis advice 347 31.89
Pneumatic compression pumps 184 16.91
Antibiotic 146 13.42
Other complex decongestive therapy 108 9.93
Physiotherapy 86 7.90
Wound dressing 76 6.99
Psychological support 68 6.25
Debulking/lymphatic surgery 11 1.01
No treatment 244 22.43
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with the LYMQOL VAS score (5.7 compared with 6.3 in our
study).6 Since there was no major difference in terms of de-
mographic and clinical characteristics, this could be due to
the fact that the Irish study has included only patients with
lower-limb chronic edema.
Regarding the EQ-5D VAS, the values reported in our
study (i.e., 63.6) denote a poor self-reported health. Indeed,
for the same set of countries, EQ-5D VAS population norms
estimated from national or regional surveys ranged between
76.8 (France) and 83.7 (Denmark) in the general population,
and between 74 (Italy) and 81.6 (Denmark) in the 55–64 age
groups.14 The 63.6 value lies below the 25th percentile for all
the available countries (i.e., Denmark, France, the UK, Ca-
nada, and Japan) with the exception of Italy. This suggests
that patients living with chronic edema are in the bottom 25%
of the general population as regards EQ-5D VAS.
Similar results are reported in a case–control study of 107
cases (82% women) matched with 102 age/sex controls in
London. EQ-5D health index scores were significantly re-
duced in the cases (66) by 13 points compared with controls
(79; p< 0.001). Results from the VAS showed a similar dif-
ference (64/76; p < 0.001). The mobility questions confirmed
the significant impact on mobility with 68 (64%) of cases
stating they had problems with walking or were confined to
a wheelchair or bed compared with only 36 (36%) of the
controls ( p < 0.001).15
EQ-5D results were also similar in a prospective cohort
design study involving the intervention of a new service
following a 6-month baseline period in the UK. QoL showed
greatest improvements between baseline and 6 months post-
implementation, the largest differences being in role physical
(d = 32.7; p = 0.0001) and role emotion (d = 24.0; p < 0.0001).
EuroQol increased following the implementation of the new
service by a mean score of 0.05 ( p = 0.007).16
In the multivariate linear models undertaken in this study,
LYMQOL VAS was significantly higher when EQ-5D VAS
was higher, and when two LYMQOL domains (function and
mood) were lower. This is consistent with the strong corre-
lation observed between the LYMQOL and EQ-5D VAS
scores. Regarding the LYMQOL domains, this result sug-
gests that the function and mood domains are the ones that
contribute the most to the overall LYMQOL VAS. Un-
fortunately, previous quantitative studies did not report such
correlation (Greene 2017).
It is interesting to note that, after adjustment, LYMQOL
VAS is not explained by any demographic or clinical variable,
as in the Irish study (Greene 2017). This suggests that LYM-
QOL VAS is a very effective way to capture the disease-
specific overall QoL. As for EQ-5D VAS, it was significantly
higher when LYMQOL VAS was higher, when the patient was
younger, nonobese, and a male. The association with age and
gender was expected because, in all countries having general
population reference norms, the EQ-5D VAS is lower for older
people and among women.14 Obesity is a condition that is
known to be associated with reduced health-related QoL.17,18
Patients with a chronic leg edema tended to declare a
higher impact of the disease on health-related QoL than pa-
tients with a chronic arm edema. This is consistent with the
Irish study that suggests a poorer overall and domain-specific
QoL in patients with a chronic lower-limb edema.6,15,16
This study suffers from some limitations that should be
acknowledged. First, the representativeness of the sample
might be questioned by the real-world observational design of
the study. But the sample is comparable in age and gender with
previous work,6 and investigators were asked to prospectively
include all consecutive patients meeting the inclusion criteria.
Moreover, we included patients with arm, leg, and other
localizations of chronic edema in different inpatient and
outpatient health care settings. Hence the risk of selection
bias was controlled as much as possible. Second, in addition
to the disease-specific LYMQOL tool, we used the generic
EQ-5D scale. One could argue that it is expected not to ac-
curately reflect the disease-specific health-related QoL;
however, we did so purposely to highlight the complemen-
tarity between both tools. Nevertheless, this multicenter, real-
life, international study has the largest sample of patients with
chronic edema among the studies reported so far. In addition,
the LIMPRINT study relies on a standardized, clinical defi-
nition of chronic edema that reduces the risk of including a
patient without a chronic edema.
To conclude, the LIMPRINT study confirms that patients
living with a chronic edema experience a poor health-related
QoL and that EQ-5D and LYMQOL seem to be comple-
mentary tools to assess this population.
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Table 4. Correlation Between the EQ-5D VAS
and the LYMQOL Scores
Pearson correlation coefficient (p-value)
LYMQOL VAS 0.79 (<0.0001)
Function -0.46 (<0.0001)
Appearance -0.31 (<0.0001)
Symptoms -0.36 (<0.0001)
Mood -0.43 (<0.0001)
VAS, visual analogue scale.
Table 5. Variables Associated with the EQ-5D
and LYMQOL VAS in Multivariate Analysis
b SE p-value
Model 1: EQ-5D VAS
LYMQOL VAS 7.85 0.19 <0.0001
Age (years) -0.08 0.03 0.002
Obesity -1.89 0.59 0.001
Male patient 3.32 1.07 0.002
Model 2: LYMQOL VAS
EQ-5D VAS 0.067 0.002 <0.001
LYMQOL function -0.21 0.05 <0.001
LYMQOL mood -0.49 0.06 <0.001
b, regression coefficient; SE, standard error; VAS, visual
analogue scale.
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